Fentanyl Buccal Tablet for Breakthrough Cancer Pain: Why Titrate?

Pain Practice ◽  
2010 ◽  
Vol 11 (2) ◽  
pp. 185-190 ◽  
Author(s):  
Ulrich R. Kleeberg ◽  
Marilène Filbet ◽  
Giovambattista Zeppetella
Keyword(s):  
Cancer Pain ◽  
Breakthrough Cancer Pain ◽  
Fentanyl Buccal Tablet ◽  
Buccal Tablet

scholarly journals Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain

2014 ◽  
Vol 19 (4) ◽  
pp. 528-537 ◽  
Author(s):  
U.R. Kleeberg ◽  
A. Davies ◽  
J. Jarosz ◽  
S. Mercadante ◽  
P. Poulain ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Dose Titration ◽  
Open Label ◽  
Breakthrough Cancer Pain ◽  
Fentanyl Buccal Tablet ◽  
Buccal Tablet ◽  
Label Dose ◽  
Titration Study

scholarly journals Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses

2012 ◽  
Vol 28 (6) ◽  
pp. 963-968 ◽  
Author(s):  
Sebastiano Mercadante ◽  
Antonio Gatti ◽  
Giampiero Porzio ◽  
Claudio Lo Presti ◽  
Federica Aielli ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Dose Titration ◽  
Breakthrough Cancer Pain ◽  
Fentanyl Buccal Tablet ◽  
Buccal Tablet

Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain

2015 ◽  
Vol 23 (7) ◽  
pp. 2135-2143 ◽  
Author(s):  
Andrew Davies ◽  
Ulrich R. Kleeberg ◽  
Jerzy Jarosz ◽  
Sebastiano Mercadante ◽  
Philippe Poulain ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Patient Functioning ◽  
Breakthrough Cancer Pain ◽  
Patients With Cancer ◽  
Fentanyl Buccal Tablet ◽  
Buccal Tablet

The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs

2020 ◽  
pp. 107815522098342
Author(s):  
Jacopo Giuliani ◽  
Francesco Fiorica ◽  
Alfredo Sacchetto ◽  
Gianfranco Franceschini ◽  
Ferdinando Vaccari ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cancer Pain ◽  
Drug Costs ◽  
Cost Effectiveness Ratio ◽  
Fentanyl Citrate ◽  
Breakthrough Cancer Pain ◽  
Fentanyl Buccal Tablet ◽  
Buccal Tablet ◽  
The Mean

The aim of this paper was to assess the drug costs of the different biotechnologies (intranasal fentanyl spray (INFS), oral transmucosal fentanyl citrate (OTFC) and fentanyl buccal tablet (FBT)) in the treatment of breakthrough cancer pain (BTCP). We have calculated the mean drug costs (expressed in euros (€)) for patients treated for BTCP. INFS resulted the less expensive towards OTFC and FBT, with 697 440 €versus (vs.) 809 552 €vs. 779 662 €every 100 patients treated for BTCP, respectively. In conclusion, combining drug costs of different biotechnologies (INFS, OTFC and FBT) with the measure of efficacy represented by the reduction of BTCP avoided (incremental cost-effectiveness ratio, ICER), INFS resulted in better cost-effectiveness.

Sign in / Sign up

Export Citation Format

Share Document